Trafalgar International Adopts Restated Charter Granting Series B Permanent 51% Voting Control
Summary
Trafalgar International restated its charter to give Series B preferred shares permanent 51% voting control and strip Series A of all conversion and voting rights, entrenching the controlling shareholder's grip on the company.
Key Events · Corporate Governance and Compliance · GCAN
-
Series B Granted Permanent 51% Voting Control
The 1,000 outstanding Series B preferred shares now collectively hold at least 51% of aggregate voting power on all matters, with votes automatically recalculated upward whenever new dilutive securities are issued.
-
Series A Conversion Rights Eliminated
All prior conversion ratios, anti-dilution provisions, and common-share reservation obligations for Series A preferred stock are eliminated, removing a potential source of future common share issuance.
-
Authorized Capital Set at 2B Common / 20M Preferred
The restated charter authorizes 2,000,000,000 common shares and 20,000,000 preferred shares, with 10,000,000 designated Series A and 1,000 designated Series B.
-
Series B Protective Consent Rights
Series B holders must approve any amendment to their voting power, any issuance of securities that could override the 51% entitlement, any merger or reorganization impairing their rights, and any change to the Series B share count.
Analysis · GCAN · Life Sciences
The board approved a full restatement of the Articles of Incorporation that gives the 1,000 outstanding Series B preferred shares a permanent, formula-driven 51% of aggregate voting power on every shareholder vote. The formula automatically adjusts Series B votes upward whenever new shares, options, warrants, or convertibles are issued, so the controlling holder can never be diluted below majority control. At the same time, Series A preferred stock loses all conversion rights, voting multipliers, and liquidation preferences — effectively neutralizing a class that previously carried economic upside. This is a governance restructuring that locks in control for the Trafalgar-affiliated Series B holder and eliminates a potential overhang from Series A conversion. The company had only $111 in cash and a going-concern warning as of its last 10-Q, so this charter change is the controlling shareholder consolidating structural power during a period of financial distress.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCAN was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $467.4K. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.